AVEO Pharmaceuticals Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (23)

Latest Posts

About This Stock More About This Stock
Week In Review: Shanghai ChemPartner, A China CRO/CMO, Completes Reverse Merger
Article By: ChinaBio® Today
Saturday, August 18, 2018 4:31 PM EDT
Shanghai ChemPartner, a CRO/CMO, closed its reverse merger with Quantum Hi-Tech China Biological (SZE: 300149) for a combination of cash and stock. ChemPartner said it will have easier access to additional capital as a listed entity.
In this article: BX, AVEO, CHNA
Read
Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals
Article By: ChinaBio® Today
Saturday, December 23, 2017 5:37 PM EDT
Nanjing Legend Biotech and Janssen Biotech will form a global partnership with Legend for its CAR-T candidate and Crown Bioscience, a CRO with facilities in China, Taiwan, US and Europe, will be acquired for $400 million by JSR Corporation of Japan.
In this article: AVEO, CELG, FPRX, TRXC, BGNE, VTVT, ZLAB
Read
HH Small Cap Biotech Stocks Soar: How Long Will Rotation Last?
Article By: Rod Raynovich
Thursday, October 5, 2017 9:06 PM EDT
Speculation in small cap biotech picks up, a boon for diligent traders. ETF buying is driving all small cap and microcap stocks higher.
In this article: AVEO, ZIOP, IJS, IWC, IWM, XBI, FPRX, RXDX, XNCR, CNCR, EDIT
Read
Premarket Biotech Digest – NOVN Reports Topline Results, INNV Receives New Patent, AIQ Signs Merger Agreement
Article By: KKD Healthcare Analytics
Wednesday, April 12, 2017 9:50 AM EDT
Novan stock skyrocketed as the company reported positive topline results from the Company’s Phase 2 clinical trial with SB208. Alliance HealthCare Services announced signing a definitive merger agreement with Tahoe Investment Group.
In this article: AIQ, PLX, AVEO, BCRX, NBIX, MZOR, NOVN
Read
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's In Store?
Article By: Zacks Investment Research
Tuesday, March 7, 2017 4:30 AM EDT
AVEO, a development-stage biopharmaceutical company, is focused on the development of treatments for cancer and other areas of unmet medical need. The company has an interesting pipeline with the most advanced candidate being tivozanib.
In this article: AVEO Also: BMY, SPPI, PETX
Read

PARTNER HEADLINES

Latest Tweets for $AVEO

No tweets yet!